DEEP VALUE: Becton Dickinson
Market cap: $16.4 billion
P/E ratio: 14
Current ratio: 2.3
Dividend yield: 1.8%
When the National Institute of Health gets its stimulus money and ramps up research projects, this medical supplies and lab equipment seller should benefit. Becton Dickinson's revenue also increases with the onset of flu season, since it is a dominant maker of flu diagnostic and treatment products.
Analysts agree that any slowdown in sales in 2009 should be offset by the company's aggressive cost-cutting program. About 65% of its sales are in products where it holds the No. 1 or No. 2 market share position; and Merrill Lynch analyst Jon Wood wrote in a recent note that the company's revenue should grow at about 6% in 2009 and continue to grow at a good clip in the beginning of 2010.
-
Abbott -
Coca-Cola -
General M... -
J&J -
P&G -
Waste Man... -
McDonald's -
FPL -
Accenture -
Chubb -
Cisco -
Microsoft -
Walgreen -
Gilead -
Mastercard -
Thermo Fi... -
Baker Hug... -
Becton Di... -
Bristol-M... -
Carlisle -
Noble -
Regal Bel... -
Valmont -
W.W. Grai... -
Aaon -
Exponent -
Lincoln E... -
Merit Med... -
Neogen -
NutriSystem -
Sykes -
Tessera -
BHP Billi... -
Diageo -
Petrobras -
Philips -
Potash -
Teva -
Total -
Unilever
Last updated June 11 2009: 10:27 AM ET
Criteria include prices no more than 15 times average earnings per share over the past three years, 10 years of positive earnings, annual per-share earnings growth of 3% or more, 10 years of uninterupted dividends, and curent ratio (assets divided by liabilities) of 2 or better. All data related to stock price as of June 1, 2009. P/E ratios based on average three-year earnings.
